Integrated Filing — IndAS

General information about company
Scrip Code	532872
NSE Symbol	SPARC
MSEI Symbol	NA
ISIN	INE232I01014
Name of company	Sun Pharma Advanced Research Company Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	19-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	12-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Pharmaceutical Research and Development
Start date and time of board meeting	19-May-2025   17:15:00
End date and time of board meeting	19-May-2025   19:15:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2025-05-19
Indicate Company website link for updated RPT policy of the Company	https://sparc.life/statutory-disclosures/policies-and-codes/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
Company does not make any default in repayment of loan.

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	271900000	717700000
	Other income	0	17900000
	Total income	271900000	735600000
2	Expenses
(a)	Cost of materials consumed	57000000	231200000
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	248300000	1089600000
(e)	Finance costs	45100000	89100000
(f)	Depreciation, depletion and amortisation expense	25500000	108300000
(f)	Other Expenses
1	Clinical trial expenses / products development expense	114800000	813300000
2	Professional charges	296200000	1412600000
3	Other expenses	94800000	443700000
	Total other expenses	505800000	2669600000
	Total expenses	881700000	4187800000
3	Total profit before exceptional items and tax	-609800000	-3452200000
4	Exceptional items	0	0
5	Total profit before tax	-609800000	-3452200000
6	Tax expense
7	Current tax	0	0
8	Deferred tax	0	0
9	Total tax expenses	0	0
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	-609800000	-3452200000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	-609800000	-3452200000
17	Other comprehensive income net of taxes	-3900000	-2500000
18	Total Comprehensive Income for the period	-613700000	-3454700000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	324500000	324500000
	Face value of equity share capital	1	1
27	Details of debt securities
22	Reserves excluding revaluation reserve		-2530700000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	-1.88	-10.64
	Diluted earnings (loss) per share from continuing operations	-1.88	-10.64
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	-1.88	-10.64
	Diluted earnings (loss) per share from continuing and discontinued operations	-1.88	-10.64
24	Debt equity ratio	0	0
25	Debt service coverage ratio	0	0
26	Interest service coverage ratio	0	0
27	Disclosure of notes on financial results		1. The above audited standalone financial results of Sun Pharma Advanced Research Company Limited the Company have been prepared in accordance with Companies Indian Accounting Standards Rules 2015 Ind AS as amended, prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and as per the Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended and have been taken on record by the Board of Directors at its meeting held on May 19 2025 after being reviewed by the Audit Committee. n n2.The Company has incurred cash losses in past quarters and in the current quarter. The Company has a support letter from its promoter group entity basis which its status as Going Concern continues. n n3.The Company has only one reportable business segment namely Pharmaceutical Research and Development. n n4.The figures for the quarter ended March 31 2025 and March 31 2024 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial years which were subject to limited review by the Statutory Auditors of the Company.

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	952700000
	Capital work-in-progress	5600000
	Investment property	0
	Goodwill	0
	Other intangible assets	600000
	Intangible assets under development	535900000
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	4200000
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	261100000
	Total non-current financial assets	265300000
	Deferred tax assets (net)	0
	Other non-current assets	1280100000
	Total non-current assets	3040200000
2	Current assets
	Inventories	0
	Current financial asset
	Current investments	0
	Trade receivables, current	160600000
	Cash and cash equivalents	11900000
	Bank balance other than cash and cash equivalents	0
	Loans, current	1600000
	Other current financial assets	23600000
	Total current financial assets	197700000
	Current tax assets (net)	0
	Other current assets	55000000
	Total current assets	252700000
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	3292900000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	324500000
	Other equity	-2530700000
	Total equity attributable to owners of parent	-2206200000
	Non controlling interest
	Total equity	-2206200000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	1000000000
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	59000000
	Total non-current financial liabilities	1059000000
	Provisions, non-current	76800000
	Deferred tax liabilities (net)	0
	Deferred government grants, Non-current	0
	Other non-current liabilities	626000000
	Total non-current liabilities	1761800000
	Current liabilities
	Current financial liabilities
	Borrowings, current	1581900000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	9400000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1234500000
	Total Trade payable	1243900000
	Other current financial liabilities	328600000
	Total current financial liabilities	3154400000
	Other current liabilities	525500000
	Provisions, current	57400000
	Current tax liabilities (Net)	0
	Deferred government grants, Current	0
	Total current liabilities	3737300000
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	5499100000
	Total equity and liabilites	3292900000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
	Total Amount of items that will not be reclassified to profit and loss
2	Income tax relating to items that will not be reclassified to profit or loss	3900000	2500000
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss	0	0
5	Total Other comprehensive income	-3900000	-2500000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			-3452200000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			89100000
	Adjustments for decrease (increase) in inventories			0
	Adjustments for decrease (increase) in trade receivables, current			-4300000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-195100000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			-10500000
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			-265600000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			-38800000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			108300000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			35700000
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			8500000
	Adjustments for dividend income			0
	Adjustments for interest income			6800000
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			0
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			-300000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-279800000
	Net cash flows from (used in) operations			-3732000000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			-107900000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			-3624100000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			5900000
	Purchase of property, plant and equipment			103400000
	Proceeds from sales of investment property			28600000
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			145500000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			1500000000
	Net cash flows from (used in) investing activities	1576600000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			5802100000
	Repayments of borrowings			3690300000
	Payments of lease liabilities			20100000
	Dividends paid			0
	Interest paid			82900000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			2008800000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			-38700000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			0
	Net increase (decrease) in cash and cash equivalents			-38700000
	Cash and cash equivalents cash flow statement at beginning of period			50600000
	Cash and cash equivalents cash flow statement at end of period			11900000